Table 1.
Clinical Features, Technology, and Insulins Used by Subjects Completing the Survey of Complications of Continuous Subcutaneous Insulin Infusion
| Parameter | Value |
|---|---|
| Number of subjects | 92 |
| Age (years) | 45.3±12.8 |
| Mean (range) diabetes duration (years) | 28.8±12.8 (2.0–67.0) |
| Median (range) duration of CSII (years) | 3.3 (0.5–32.0) |
| Mean (range) duration of infusion set use (days) | 3.2±0.7 (2.0–6) |
| Pump manufacturer (% of subjects) | |
| Medtronic | 84.8 |
| Roche | 9.8 |
| Animas | 5.4 |
| Pump insulin (% of subjects) | |
| Aspart | 55.8 |
| Lispro | 40.7 |
| Glulisine | 3.5 |
| Infusion set (% of subjects) | |
| Medtronic Quick-Seta | 72.0 |
| Medtronic Mioa | 6.5 |
| Animas Insetb | 5.4 |
| ACCU-CHEK FlexLinkb | 4.3 |
| Medtronic Silhouettea | 4.3 |
| Medtronic Sure-Tb | 3.2 |
| ACCU-CHEK Tendera | 3.2 |
| ACCU-CHEK Rapid-Db | 1.1 |
a
Teflon.
b
Metal.
CSII, continuous subcutaneous insulin infusion.